Pascal Soriot, Managing Director of AstraZeneca. Photograph: Brenda Goh / Reuters

AstraZeneca chief executive said it was possible the current coronavirus spike in Europe could be linked to governments’ decision not to use the company’s Covid-19 vaccine in the elderly.

After an article in a German newspaper which turned out to be false, the effectiveness of AstraZeneca vaccine in the elderly was questioned, and several European governments initially chose not to use it in the elderly. over 60 or over 65.

Germany, for example, then overturned its earlier verdict and approved the vaccine for those over 65 in March after further studies found it to be safe and effective. Public confidence in the jab was also eroded when a rare link to blood clots emerged.

Public confidence in the jab eroded, also when a rare link to blood clots emerged.

Pascal SoriotAstraZeneca CEO insisted he has no regrets about the vaccine as the company unveils a £ 1 billion research and development (R&D) center in Cambridge, the world’s largest science laboratory UK and AstraZeneca’s biggest investment ever.

Speaking on BBC Radio 4 today program, Soriot explained that the Covid-19 vaccines do two things: stimulate an antibody response and a T-cell response.

“The T cell response takes a bit longer to come in, but it’s actually longer lasting, it lasts longer, and the body remembers it longer,” he said.


“The antibodies decrease over time … What remains, and this is very important, is this T lymphocyte response.

You can be infected, but they come to the rescue and you are not hospitalized.

Soriot added that this could explain why the UK has recorded relatively fewer hospitalizations in the current wave of Covid-19:


“In the UK there has been a sharp increase in infections but not as many hospitalizations compared to Europe.

In the UK this vaccine was used to immunize the elderly, while in Europe people initially thought the vaccine did not work in the elderly.


[Explainer: AstraZeneca’s vaccine, developed at Oxford University, used a modified adenovirus with the Covid-19 spike protein to induce an immune response.

Other vaccines, such as Pfizer’s, use mRNA technology with the genetic instructions for the vaccinated person’s own cells to produce the vaccine antigens].

Q: So could there be a link between the increase in cases and hospitalizations in Europe, and the fact that the AstraZeneca vaccine was not used there in the elderly?

Soriot replies:


“T cells are important and in particular are linked to the sustainability of the response, especially in the elderly, and this vaccine has been shown to stimulate T cells more in the elderly.

We haven’t seen a lot of hospitalizations in the UK, a lot of infections, of course. But what matters is: are you seriously ill or not? Are you hospitalized or not?

Q: And could this be because the AstraZeneca vaccine has been used in older people in the UK?

Soriot says more data is needed to know the answer:


“It’s possible, but there’s no proof of anything. We need more data to analyze this and get the answer.

BBC Radio 4 Today
(@ BBCr4today)

“What matters is, are you seriously ill or not?” And we have not seen so many of these hospitalizations ”

AstraZeneca boss Pascal Soriot raises the possibility that the AZ vaccine could possibly be considered more effective than those selected for the British booster shots https://t.co/qHGb9xqhz0 pic.twitter.com/bFdF59yuRS


23 November 2021

prince charles will officially open AstraZeneca’s R&D center on Tuesday, as the company aims to accelerate its development of new pharmaceuticals.

It will house more than 2,200 researchers and is one of AZ’s three main R&D centers with one in the United States and one in Gothenburg, Sweden. The Anglo-Swedish drugmaker, Britain’s largest pharmaceutical company, invests more than $ 7 billion in R&D annually worldwide, much of which takes place in the UK.

BBC Radio 4 Today
(@ BBCr4today)

“When I found this land, I got so excited because of the location”

AstraZeneca boss Pascal Soriot tells @JustinOnWeb that the Cambridge “ecosystem” made up of different scientific research companies has become comparable to that of Stanfordhttps: //t.co/ZfOUkArFbu # R4Today pic.twitter.com/rQhnTfEleK


23 November 2021

AstraZeneca has been one of the few vaccine makers to sell its vaccine at cost, but is now signing commercial contracts for next year, moving away from its nonprofit pricing.

Oxford professors Sir Andrew Pollard and Brian angus today called on governments with vaccine doses available to do their utmost to ensure that they urgently reach undecided and unvaccinated people:



Source link

About The Author

Related Posts